Overview

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe, and North and South America. The aim of this clinical trial is to investigate the safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in male previously treated paediatric subjects with haemophilia A.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Factor VIII